Phase II Prospective, Open-Label Randomized Controlled Trial Comparing Standard of Care Chemotherapy With and Without Sequential Cytoreductive Interventions for Patients with Oligometastatic Foregut Adenocarcinoma and Undetectable Circulating Tumor Deoxyribose Nucleic Acid (ctDNA) Levels-Reference-Cited by-同舟云学术

Phase II Prospective, Open-Label Randomized Controlled Trial Comparing Standard of Care Chemotherapy With and Without Sequential Cytoreductive Interventions for Patients with Oligometastatic Foregut Adenocarcinoma and Undetectable Circulating Tumor Deoxyribose Nucleic Acid (ctDNA) Levels

Published:2022-01-05 Issue:7 Volume:29 Page:4583-4592
ISSN:1068-9265
Container-title:Annals of Surgical Oncology
language:en
Short-container-title:Ann Surg Oncol

Author:

Dhiman Ankit,Vining Charles C.,Witmer Hunter D. D.,Sood Divya,Shergill Ardaman,Kindler Hedy,Roggin Kevin K.,Posner Mitchell C.,Ahmed Osmanuddin S.,Liauw Stanley,Pitroda Sean,Liao Chih-Yi,Karrison Theodore,Weichselbaum Ralph,Polite Blase,Eng Oliver S.,Catenacci Daniel V. T.,Turaga Kiran K.

Publisher

Springer Science and Business Media LLC

Subject

Oncology,Surgery

Link

https://link.springer.com/content/pdf/10.1245/s10434-021-11249-7.pdf

Reference48 articles.

1. Sung H, Ferlay J, Siegel RL, et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2021;71(3):209–49. https://doi.org/10.3322/caac.21660.

2. Ajani JA, D’Amico TA, Almhanna K, et al. Gastric cancer, version 3.2016, NCCN clinical practice guidelines in oncology. J Natl Compr Canc Netw. 2016;14(10):1286–312. https://doi.org/10.6004/jnccn.2016.0137.

3. Ajani JA, D’Amico TA, Bentrem DJ, et al. Esophageal and esophagogastric junction cancers, version 2.2019, NCCN clinical practice guidelines in oncology. J Natl Compr Canc Netw. 2019;17(7):855–83. https://doi.org/10.6004/jnccn.2019.0033.

4. Tempero MA, Malafa MP, Chiorean EG, et al. Pancreatic adenocarcinoma, version 1.2019. J Natl Compr Canc Netw. 2019;17(3):202–10. https://doi.org/10.6004/jnccn.2019.0014.

5. Al-Batran SE, Hofheinz RD, Reichart A, et al. Quality of life and outcome of patients with metastatic pancreatic cancer receiving first-line chemotherapy with nab-paclitaxel and gemcitabine: real-life results from the prospective QOLIXANE trial of the platform for outcome, quality of life and translational research on pancreatic cancer registry. Int J Cancer. 2021;148(6):1478–88. https://doi.org/10.1002/ijc.33336.

Cited by 6 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. European clinical practice guidelines for the definition, diagnosis, and treatment of oligometastatic esophagogastric cancer (OMEC-4);European Journal of Cancer;2024-06

2. Oligometastatic disease in esophagogastric cancer: an update of recommendations on definition, diagnosis, and treatment;ESMO Gastrointestinal Oncology;2023-12

3. Use of Circulating Tumor DNA to Monitor Minimal Residual Disease Among Patients With Colorectal Cancer;Clinical Journal of Oncology Nursing;2023-07-24

4. Role of Tumor-informed Personalized Circulating Tumor DNA Assay in Informing Recurrence in Patients With Peritoneal Metastases From Colorectal and High-grade Appendix Cancer Undergoing Curative-intent Surgery;Annals of Surgery;2023-03-30

5. The oligometastatic spectrum in the era of improved detection and modern systemic therapy;Nature Reviews Clinical Oncology;2022-07-12